Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its abstract entitled "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN. The conference theme is "Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes."
新澤西州弗洛勒姆公園,2024年4月18日(GLOBE NEWSWIRE)——開發胎盤衍生異基因細胞療法和先進生物材料產品的再生醫學公司Celularity Inc.(納斯達克股票代碼:Celularity)(“Celularity”)今天宣佈,其題爲 “肌腱損傷管理和保護的新興技術:去細胞化胎盤生物材料” 的摘要已獲接受由骨科研究學會(ORS)肌腱會議主辦,該會議將於2024年5月30日至6月1日在明尼蘇達州羅切斯特的梅奧診所舉行。會議主題是 “治療機制——新興技術和治療結果”。
Celularity's abstract explores the application of various decellularized placental biomaterials, including connective tissue matrix (CTM) and umbilical cord matrix (UCM), in tendon management, both in vitro and in vivo. The abstract focuses on assessing the biomaterials' biomechanical properties, immunomodulatory effects, and preclinical outcomes in clinically relevant models to advance their potential in tendon repair.
Celularity的摘要探討了包括結締組織基質(CTM)和臍帶基質(UCM)在內的各種去細胞化胎盤生物材料在體外和體內肌腱管理中的應用。該摘要側重於評估生物材料的生物力學特性、免疫調節作用和臨床相關模型中的臨床前結果,以提高其在肌腱修復中的潛力。
Robert J. Hariri, M.D., Ph.D., Celularity Chairman, CEO and Founder, noted, "Tendon injuries, whether due to sports-related activities, overuse, or degenerative conditions, present significant challenges in both treatment and recovery. I am very excited about the growing opportunity and potential of our decellularized placental biomaterials in tendon management and healing. The global tendon market accounted for USD 2.3 billion in 2022 and is projected to achieve a market size of USD 4.8 billion by 2032, growing at a CAGR of 7.6% from 2023 to 2032. We are committed to to growing our regenerative biomaterials business through innovations like this which we believe will significantly contribute to revenue growth. I am confident Celularity's placental technology can be an important therapeutic tool in the management of these debilitating injuries."
Celularity董事長、首席執行官兼創始人羅伯特·哈里里醫學博士、博士指出:“肌腱損傷,無論是由於運動相關活動、過度使用還是退行性疾病,都對治療和康復構成重大挑戰。我們的去細胞化胎盤生物材料在肌腱管理和癒合方面的機會和潛力越來越大,這讓我感到非常興奮。2022年,全球肌腱市場佔23億美元,預計到2032年將達到48億美元的市場規模,從2023年到2032年將以7.6%的複合年增長率增長。我們致力於通過這樣的創新來發展我們的再生生物材料業務,我們認爲這將極大地促進收入增長。我相信,Celularity的胎盤技術可以成爲管理這些使人衰弱的損傷的重要治療工具。”
Anna Gosiewska, Ph.D., Vice President of Research and Development for Degenerative Diseases, who leads Celularity's development of advanced biomaterials and cell technologies, added, "Decellularized placental biomaterials offer a rich source of native, developmentally early extracellular matrix that we believe is beneficial for tissue repair and regeneration. By carefully processing and engineering these biomaterials, Celularity is developing advanced therapeutic solutions tailored specifically for tendon injuries. We believe our innovative technologies utilizing decellularized placental biomaterials represent a novel approach in the field of tendon injury management and may offer patients and healthcare providers new hope for improved outcomes and enhanced quality of life."
領導Celularity先進生物材料和細胞技術開發的退行性疾病研發副總裁Anna Gosiewska博士補充說:“脫細胞化胎盤生物材料提供了豐富的天然發育早期細胞外基質來源,我們認爲這種基質有益於組織修復和再生。通過精心加工和設計這些生物材料,Celularity 正在開發專爲肌腱損傷量身定製的先進治療解決方案。我們相信,我們利用去細胞化胎盤生物材料的創新技術是肌腱損傷管理領域的一種新方法,可能會爲患者和醫療保健提供者提供改善預後和提高生活質量的新希望。”
The study results described in the abstract provide insights into an in vivo evaluation of Celularity's decellularized placental biomaterials in two clinically relevant models. The results demonstrate more advanced healing in the UCM treated group and complete incorporation of UCM into the tendon within three months post-implantation. These data indicate that human placental decellularized biomaterials may represent a promising matrix suitable for tendon management and healing.
摘要中描述的研究結果爲在兩個臨床相關模型中對Celularity的去細胞化胎盤生物材料進行體內評估提供了見解。結果表明,UCM治療組的癒合程度更高,植入後三個月內UCM完全融入肌腱。這些數據表明,人類胎盤脫細胞生物材料可能是一種有前景的基質,適用於肌腱管理和癒合。
Through strategic collaborations with leading academic institutions and healthcare partners, Celularity is working to advance treatments for musculoskeletal disorders and beyond.
通過與領先的學術機構和醫療保健合作伙伴的戰略合作,Celularity正在努力推進肌肉骨骼疾病及其他疾病的治療。
The Celularity abstract authors include Dr. Anna Gosiewska, Desiree Long, Dr. Raja Sivalenka, Joseph Gleason, Dr. Adrian Kilcoyne, Dr. Robert J Hariri, and Dr. Steve A Brigido. The study was performed in close collaboration with scientific leaders from some of the nation's top research organizations.
Celularity 摘要作者包括安娜·戈西耶夫斯卡博士、西瑞·朗、拉賈·西瓦倫卡博士、約瑟夫·格里森、阿德里安·基爾科因博士、羅伯特·哈里里博士和史蒂夫·布里吉多博士。該研究是與美國一些頂級研究機構的科學領袖密切合作進行的。